NASDAQ:NRXP

NRx Pharmaceuticals Q3 2026 Earnings Results & Report

NRx Pharmaceuticals logo
$2.15 -0.04 (-1.83%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$2.17 +0.02 (+0.93%)
As of 11/16/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NRx Pharmaceuticals beat analyst earnings expectations but missed on revenue in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$0.05 versus the -$0.2125 consensus estimate, while revenue of $1.16 million fell short of the $1.29 million estimate by $126.00 thousand.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call Date
Conference Call
8:00 AM ET
Upcoming Event
Earnings Conference Call
NRx Pharmaceuticals Q3 2026
00:00 / 00:00
Live Transcript
Follow Audio

NRx Pharmaceuticals EPS Results

Actual EPS
-$0.05
Consensus EPS
-$0.2125
Beat/Miss
Beat by +$0.1625
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

NRx Pharmaceuticals Revenue Results

Actual Revenue
$1.16 million
Expected Revenue
$1.29 million
Beat/Miss
Missed by -$126.00 thousand
YoY Revenue Growth
N/A

Earnings Documents

NRx Pharmaceuticals Q3 2026 Earnings FAQ

NRx Pharmaceuticals (NASDAQ:NRXP) reported earnings of -$0.05 per share for Q3 2026, beating the consensus estimate of -$0.2125. The report was announced on Monday, November 16, 2026.

NRx Pharmaceuticals reported revenue of $1.16 million for Q3 2026, against a consensus estimate of $1.29 million.

NRx Pharmaceuticals Earnings Headlines

NRX Pharmaceuticals (NRXP) Gets a Buy from BTIG
You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
HC Wainwright Issues Negative Forecast for NRXP Earnings
NRx Pharmaceuticals (NRXP) Set to Post Quarterly Earnings on Friday
See More NRx Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NRx Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NRx Pharmaceuticals and other key companies, straight to your email.

About NRx Pharmaceuticals

NRx Pharmaceuticals (NASDAQ:NRXP) is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a focus on depression and conditions involving suicidal ideation. Its programs are investigational and have not been established as approved treatments.

The company’s candidates include NRX-100, a preservative-free formulation of ketamine, and NRX-101, an oral combination of D-cycloserine and lurasidone. NRx has studied these therapies for severe depression and bipolar depression, including in patients with suicidal ideation.

NRx conducts drug development primarily in the United States. Its work includes clinical research and regulatory development aimed at addressing unmet needs in mental health care.

View NRx Pharmaceuticals Profile